AHA 2021: Novel Oral PCSK9 Inhibitor Shows Promise in Phase I Trials
The investigational agent was well-tolerated and reduced LDL cholesterol
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
The investigational agent was well-tolerated and reduced LDL cholesterol
Only registered members have full access to PracticeUpdate content.